scholarly journals Experimental Adaptation of the Yellow Fever Virus to the Mosquito Aedes albopictus and Potential risk of urban epidemics in Brazil, South America

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Fadila Amraoui ◽  
Adrien Pain ◽  
Géraldine Piorkowski ◽  
Marie Vazeille ◽  
Dinair Couto-Lima ◽  
...  
2018 ◽  
Vol 64 (6) ◽  
pp. 498-500 ◽  
Author(s):  
Michelle Larissa Zini Lise ◽  
Michael Laurence Zini Lise

SUMMARY The Yellow Fever virus was isolated in 1927 and the disease is considered endemic and epidemic in tropical regions of South America and Africa, with thousands of new cases reported annually. Several side effects of the vaccine have already been reported. Although reports of skin rash secondary to the vaccine range from 0 to 15%, no image or detailed description of the lesions were found in the literature. Here we describe a rash on a toddler vaccinated to travel.


2019 ◽  
Vol 8 (1) ◽  
pp. 1636-1641 ◽  
Author(s):  
Basile Kamgang ◽  
Marie Vazeille ◽  
Aurélie P. Yougang ◽  
Armel N. Tedjou ◽  
Theodel A. Wilson-Bahun ◽  
...  

Author(s):  
Raphaëlle Klitting ◽  
Carlo Fischer ◽  
Jan F. Drexler ◽  
Ernest A. Gould ◽  
David Roiz ◽  
...  

As revealed by the recent resurgence of yellow fever virus (YFV) activity in the tropical regions of Africa and South America, YFV control measures need urgent rethinking. Over the last decade, most reported outbreaks occurred in, or eventually reached, areas of low vaccination coverage but suitable for virus transmission, with an unprecedented risk of expansion to densely populated territories in Africa, South America and Asia. As reflected in the World Health Organization’s initiative launched in 2017, it is high time to strengthen epidemiological surveillance to monitor accurately, viral dissemination and redefine vaccination recommendation areas. Vector-control and immunisation measures need to be adapted and vaccine manufacturing must be reconciled with an increasing demand. We will have to face more YF cases in the upcoming years hence, improving disease management through the development of efficient treatments will prove most beneficial. Undoubtedly, these developments will require in-depth descriptions of YFV biology at molecular, physiological and ecological levels. This second section of the two-part review describes the current state of knowledge and gaps regarding the molecular biology of YFV, along with an overview of the tools that can be used to manage the disease at the individual, local and global levels.


2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Dinair Couto-Lima ◽  
Yoann Madec ◽  
Maria Ignez Bersot ◽  
Stephanie Silva Campos ◽  
Monique de Albuquerque Motta ◽  
...  

2016 ◽  
Vol 21 (39) ◽  
Author(s):  
Fadila Amraoui ◽  
Marie Vazeille ◽  
Anna Bella Failloux

We assessed the ability of a French population of Aedes albopictus to transmit yellow fever virus (YFV). Batches of 30 to 40 female mosquitoes were analysed at 7, 14 and 21 days post-exposure (dpe). Bodies, heads and saliva were screened for YFV. Infectious viral particles were detected in bodies and heads at 7, 14 and 21 dpe whereas the virus was found in saliva only from 14 dpe. Our results showed that Ae. albopictus can potentially transmit YFV.


Genes ◽  
2018 ◽  
Vol 9 (9) ◽  
pp. 425 ◽  
Author(s):  
Raphaëlle Klitting ◽  
Carlo Fischer ◽  
Jan Drexler ◽  
Ernest Gould ◽  
David Roiz ◽  
...  

As revealed by the recent resurgence of yellow fever virus (YFV) activity in the tropical regions of Africa and South America, YFV control measures need urgent rethinking. Over the last decade, most reported outbreaks occurred in, or eventually reached, areas with low vaccination coverage but that are suitable for virus transmission, with an unprecedented risk of expansion to densely populated territories in Africa, South America and Asia. As reflected in the World Health Organization’s initiative launched in 2017, it is high time to strengthen epidemiological surveillance to monitor accurately viral dissemination, and redefine vaccination recommendation areas. Vector-control and immunisation measures need to be adapted and vaccine manufacturing must be reconciled with an increasing demand. We will have to face more yellow fever (YF) cases in the upcoming years. Hence, improving disease management through the development of efficient treatments will prove most beneficial. Undoubtedly, these developments will require in-depth descriptions of YFV biology at molecular, physiological and ecological levels. This second section of a two-part review describes the current state of knowledge and gaps regarding the molecular biology of YFV, along with an overview of the tools that can be used to manage the disease at the individual, local and global levels.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Arran Hamlet ◽  
Daniel Garkauskas Ramos ◽  
Katy A. M. Gaythorpe ◽  
Alessandro Pecego Martins Romano ◽  
Tini Garske ◽  
...  

AbstractYellow fever virus (YFV) is a zoonotic arbovirus affecting both humans and non-human primates (NHP’s) in Africa and South America. Previous descriptions of YF’s seasonality have relied purely on climatic explanations, despite the high proportion of cases occurring in people involved in agriculture. We use a series of random forest classification models to predict the monthly occurrence of YF in humans and NHP’s across Brazil, by fitting four classes of covariates related to the seasonality of climate and agriculture (planting and harvesting), crop output and host demography. We find that models captured seasonal YF reporting in humans and NHPs when they considered seasonality of agriculture rather than climate, particularly for monthly aggregated reports. These findings illustrate the seasonality of exposure, through agriculture, as a component of zoonotic spillover. Additionally, by highlighting crop types and anthropogenic seasonality, these results could directly identify areas at highest risk of zoonotic spillover.


2021 ◽  
Author(s):  
Denise Haslwanter ◽  
Gorka Lasso ◽  
Anna Z Wec ◽  
Nathalia Dias Furtado ◽  
Lidiane Menezes Souza Raphael ◽  
...  

The resurgence of yellow fever in South America has prompted mitigation through vaccination against the etiologic agent, yellow fever virus (YFV). Current vaccines are based on a virulent African isolate, and their capacity to induce neutralizing antibodies against the vaccine strain is widely used as a surrogate for protection. However, the sensitivity of genetically distinct South American strains to vaccine-induced antibodies is unknown. Here, we show that antiviral potency of the polyclonal antibody response in both U.S. and Brazilian vaccinees is attenuated against an emergent Brazilian strain. This reduction was attributable to genetic changes at two sites in the central domain II of the glycoprotein E, including the acquisition of an N linked glycosylation site, which are unique to and shared among most South American YFV strains. Our findings call for a reevaluation of current approaches to YFV immunological surveillance in South America and suggest approaches for designing updated vaccines.


1929 ◽  
Vol 50 (6) ◽  
pp. 803-808 ◽  
Author(s):  
Nelson C. Davis ◽  
Raymond C. Shannon

1. Yellow fever virus has been transmitted from monkey to monkey both by the bites of Aëdes (Ochlerotatus) scapularis which had fed upon monkeys infected with yellow fever and by the injection of the ground up bodies of such mosquitoes. 2. A fatal infection has been obtained by the injection of the ground up bodies of Aëdes (Ochlerotatus) serratus, which had previously fed on an infected monkey, and a mild infection has been secured by the similar injection of Aëdes (Taeniorhynchus) taeniorhynchus. 3. No definite infection has been secured either by the bites or by the injection of Culex quinquefasciatus (C. fatigans). However, some of the experimental animals bitten by this species have been relatively immune following inoculations of blood or tissues containing virus.


Sign in / Sign up

Export Citation Format

Share Document